State Street Corp Sells 1,805,779 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

State Street Corp trimmed its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 59.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,246,613 shares of the company's stock after selling 1,805,779 shares during the period. State Street Corp owned approximately 1.75% of Zentalis Pharmaceuticals worth $4,588,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Decheng Capital LLC raised its holdings in Zentalis Pharmaceuticals by 46.2% during the second quarter. Decheng Capital LLC now owns 3,070,442 shares of the company's stock worth $12,558,000 after buying an additional 970,859 shares during the last quarter. Verition Fund Management LLC increased its position in shares of Zentalis Pharmaceuticals by 172.1% during the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company's stock worth $5,536,000 after acquiring an additional 951,500 shares in the last quarter. Primecap Management Co. CA raised its holdings in shares of Zentalis Pharmaceuticals by 21.6% in the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company's stock worth $5,513,000 after acquiring an additional 265,690 shares during the last quarter. Renaissance Technologies LLC lifted its position in Zentalis Pharmaceuticals by 152.6% in the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company's stock valued at $2,706,000 after acquiring an additional 399,745 shares in the last quarter. Finally, GSA Capital Partners LLP boosted its stake in Zentalis Pharmaceuticals by 138.5% during the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company's stock valued at $2,240,000 after purchasing an additional 353,384 shares during the last quarter.

Zentalis Pharmaceuticals Trading Down 4.6 %

Shares of NASDAQ:ZNTL traded down $0.14 during midday trading on Monday, reaching $2.92. The company had a trading volume of 1,535,732 shares, compared to its average volume of 1,298,110. The stock has a market cap of $208.09 million, a P/E ratio of -1.17 and a beta of 1.84. The company's 50 day moving average price is $3.34 and its 200 day moving average price is $3.64. Zentalis Pharmaceuticals, Inc. has a 52-week low of $2.66 and a 52-week high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.36. Research analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Oppenheimer reissued an "outperform" rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Finally, Guggenheim cut their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating on the stock in a report on Friday, November 15th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $10.00.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.